Microarrays remain one of the workhorse tools of modern genetics because they let researchers measure huge numbers of DNA features at once on a single chip. In the source material, Illumina presents microarrays not as one narrow product but as a broad platform for genotyping, methylation analysis, species-specific breeding studies, and customized testing programs. The core idea is simple: instead of checking one genetic marker at a time, a microarray acts like a massively parallel checklist, scanning thousands to millions of predefined sites across the genome in one run. That makes the technology useful in settings that range from livestock selection to population-specific health tests and large disease studies. The company also highlights its newer Infinium EX workflow, which it says improves throughput, shortens the process, and cuts the DNA input requirement in half compared with earlier protocols. Alongside the hardware and chemistry, the source points to partnerships designed to make the resulting data more interpretable, including efforts in Asian population testing and consumer reporting. Taken together, the story is less about a single experiment than about how one mature biochip technology is being adapted for faster workflows, more tailored content, and more practical uses in research and health.
What microarrays actually do
A microarray is a small chip covered with many probes, which are short pieces of DNA designed to recognize specific genetic sequences. If a sample contains a matching sequence, it binds to the probe, allowing software to read out which variants are present across a very large panel.
An easy analogy is a supermarket barcode scanner with millions of tiny checkpoints instead of one beam of light. Each checkpoint looks for one known feature, and together they create a broad genetic snapshot quickly and at relatively high scale.
From human studies to animal breeding
The source emphasizes non-human genotyping arrays for tasks such as whole-genome selection studies, DNA fingerprinting, net merit evaluation, and marker-assisted breeding. In plain terms, these arrays help breeders and researchers identify inherited traits and select animals or plant lines based on genetic markers linked to performance or ancestry.
This matters because breeding decisions often depend on screening very large populations. Species-specific catalog arrays and consortia-developed designs give researchers a ready-made way to test the markers most relevant to cattle, crops, or other organisms, while custom arrays can be built for less common species or specialized breeding goals.
Reading the epigenome with methylation arrays
The source also describes methylation arrays, which measure epigenetic patterns across the genome. Epigenetics refers to chemical marks that affect how genes are used without changing the DNA sequence itself, and DNA methylation is one of the best-studied examples.
Illumina says these arrays can quantify changes in CpG islands, non-CpG sites, differentially methylated regions, and regulatory regions at single-nucleotide resolution. Think of methylation as sticky notes attached to the genome: the words in the book stay the same, but the notes can signal which passages should be emphasized, muted, or skipped by the cell.
Why customization is a big deal
One of the strongest themes in the source is customization. Rather than relying only on standard content, researchers can use custom genotyping designs to screen large sample sets against novel targets or regions tied to a specific question.
That flexibility is important because many studies do not need a one-size-fits-all array. A team focused on one disease pathway, one agricultural trait, or one population can concentrate the chip's real estate on the markers most likely to produce useful answers, which can improve efficiency and reduce unnecessary data collection.
Population-specific testing and data interpretation
The source gives two examples of how microarrays are being adapted beyond generic catalog use. Genesis Healthcare is developing kits based on Illumina microarrays with genetic markers described as unique to Asian populations, specifically for Japan and Southeast Asia.
That points to a long-running issue in genetics: tests built mainly from European datasets may not perform as well in other populations. A population-specific marker set can, in principle, improve relevance by making sure the array includes variants that are more informative for the people being tested.
The source also notes a partnership between MyDNA and Illumina. In that arrangement, MyDNA provides software intended to help customers interpret the data coming off the array and turn raw genetic signals into more understandable reports.
A faster workflow with Infinium EX
Beyond array content, Illumina frames the laboratory workflow itself as a major update. The company says researchers can choose ready-to-use microarrays or create custom iSelect and semicustom arrays, then move through a rapid DNA-to-data process for handling and scanning samples.
Its latest platform, Infinium EX, is presented as the most advanced version of that workflow. According to the source, the protocol offers higher throughput, broad coverage, improved imputation accuracy, shorter workflows, and requires only half as much DNA as previous protocols.
Imputation accuracy needs a quick translation because it is a technical term. Imputation is a statistical method that infers genetic variants that were not directly measured on the chip by using patterns seen in reference datasets; better accuracy means those educated guesses are more reliable.
Featured research and polygenic risk scores
The source connects microarrays to one of the most closely watched trends in medical genetics: polygenic risk scores, or PRSs. These scores combine the small effects of many genetic variants to estimate a person's inherited risk for a disease.
Illumina highlights research using the Global Screening Array in large genome-wide association studies, often called GWAS, to identify disease-linked loci and develop PRSs for clinical validation. A GWAS looks across the genomes of many people to find variants that appear more often in those with a particular disease or trait.
Why This Matters
Microarrays sit in an interesting middle ground in genomics. They do not read every letter of DNA the way full sequencing can, but they are fast, scalable, and highly useful when researchers know which markers they want to track across many samples.
That makes them especially practical for population studies, breeding programs, methylation profiling, and clinical research pipelines that need consistency more than unlimited discovery. The source's examples also show the next step for biochips: not just collecting more data, but collecting the right data for a species, population, or application and pairing it with software that can explain what the output means.
The larger takeaway is that microarrays are evolving from generic genotyping tools into more specialized platforms with tighter workflows and more tailored content. As groups continue building custom panels, region-specific tests, and clinically oriented risk models, the value of the technology will likely depend less on raw chip density and more on how well each array matches the biological question it is meant to answer.